Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Infinity Doesn't Sugarcoat Disappointing Duvelisib Data; Cuts R&D Staff To Preserve Cash

Executive Summary

Infinity's hopes for accelerated approval of duvelisib based on the DYNAMO study have been dashed, so as the company plots a new strategy for the PI3K inhibitor – with or without its partner AbbVie – it has cut discovery research operations, including 46 jobs.


Related Content

Verastem Sees Phase III Success With PIK3 Inhibitor Dropped By AbbVie
Deal Watch: Bristol Leaves Neuropathic Pain Candidate To Lexicon
Stockwatch: A Week Of Dashed Expectations
Venclexta Win Broadens AbbVie/Genentech CLL Positions
AbbVie outdoes rumored J&J bid with $21bn Pharmacyclics buy
Infinity PhII results a blow for PI3K in inflammation
Infinity's horizons broaden with rich AbbVie co-development deal
Infinity will not go beyond Phase II with retaspimycin
Infinity cuts 20% of workforce as it refocuses on PI3K and retaspimycin
Infinity minus one: shares plummet as spiky saridegib fails in pancreatic cancer


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts